On Monday, Sage Therapeutics Inc (NASDAQ: SAGE) opened lower -3.03% from the last session, before settling in for the closing price of $5.61. Price fluctuations for SAGE have ranged from $4.62 to $28.26 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 3395.58%. Company’s average yearly earnings per share was noted 28.22% at the time writing. With a float of $53.88 million, this company’s outstanding shares have now reached $61.17 million.
Let’s determine the extent of company efficiency that accounts for 487 employees. In terms of profitability, gross margin is 91.75%, operating margin of -349.3%, and the pretax margin is -317.29%.
Sage Therapeutics Inc (SAGE) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Sage Therapeutics Inc is 11.92%, while institutional ownership is 85.29%. The most recent insider transaction that took place on Dec 10 ’24, was worth 41,441.
Sage Therapeutics Inc (SAGE) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 28.22% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.80% during the next five years compared to -2.28% drop over the previous five years of trading.
Sage Therapeutics Inc (NASDAQ: SAGE) Trading Performance Indicators
Check out the current performance indicators for Sage Therapeutics Inc (SAGE). In the past quarter, the stock posted a quick ratio of 10.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.58, a number that is poised to hit -1.52 in the next quarter and is forecasted to reach -3.76 in one year’s time.
Technical Analysis of Sage Therapeutics Inc (SAGE)
Looking closely at Sage Therapeutics Inc (NASDAQ: SAGE), its last 5-days average volume was 2.4 million, which is a jump from its year-to-date volume of 1.0 million. As of the previous 9 days, the stock’s Stochastic %D was 42.27%. Additionally, its Average True Range was 0.40.
During the past 100 days, Sage Therapeutics Inc’s (SAGE) raw stochastic average was set at 16.25%, which indicates a significant decrease from 51.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.61% in the past 14 days, which was lower than the 73.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.07, while its 200-day Moving Average is $10.16. However, in the short run, Sage Therapeutics Inc’s stock first resistance to watch stands at $5.68. Second resistance stands at $5.93. The third major resistance level sits at $6.09. If the price goes on to break the first support level at $5.28, it is likely to go to the next support level at $5.12. Now, if the price goes above the second support level, the third support stands at $4.87.
Sage Therapeutics Inc (NASDAQ: SAGE) Key Stats
There are currently 61,173K shares outstanding in the company with a market cap of 332.78 million. Presently, the company’s annual sales total 86,460 K according to its annual income of -541,490 K. Last quarter, the company’s sales amounted to 11,870 K and its income totaled -93,550 K.
